We’re thrilled to share that we’ve successfully completed the NSF I-Corps program at the New York Hub! This program has been a pivotal experience for us, providing valuable insights into customer discovery and further validating the impact of our AI-powered, physics-guided platform. Over the course of the program, we conducted 100 interviews with scientists, decision-makers at large pharmaceutical and biotech companies, software experts, and venture capitalists. These conversations have allowed us to refine our understanding of the market and the challenges drug discovery teams face.
We’ve found that over 80% of therapeutic targets are considered “undruggable” due to hidden binding sites missed by conventional methods. With our platform, which generates realistic protein conformations in just 4–6 hours (compared to the months required by traditional molecular dynamics), we’re enabling drug discovery teams to uncover novel targets and accelerate early-stage development. The insights from the NSF I-Corps program have sharpened our ability to help scientists unlock these elusive binding sites, and we’re excited to continue pushing the boundaries of what’s possible in drug discovery.